PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
이익 전환
회사의 실적이 흑자로 전환되어, 최근 연간 순이익은 미화 23.36M달러에 달합니다.%!(EXTRA int=2)
공정한 가치
회사의 최신 PE은 0.31로, 최근 3년 기준 중간 백분위 범위에 속합니다.
기관 매도
최신 기관 보유 주식 수는 1.28M주이며, 전 분기 대비 28.93% 감소했습니다.
더 뱅가드가 보유
스타 투자자 더 뱅가드이(가) 이 주식 194.45K주를 보유하고 있습니다.
시장 활동 증가
회사는 투자자들의 관심이 높아져, 최근 20일간 회전율이 4.02입니다.